Viridian Therapeutics had its Relative Strength (RS) Rating upgraded from 63 to 82 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 in the early stages of their moves.
While Viridian Therapeutics is not near a proper buying range right now, see if it goes on to form and break out from a proper base.
The company showed 0% earnings growth in the latest quarterly report. Revenue rose 14%.
Viridian Therapeutics holds the No. 263 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
